B1: 5'-GGAGCGGGCTGTCTCAGA-3' Figure S1 . Expression of BRAF and RAF1 in melanomas. Cell lysates from the melanoma cell strains used in our studies were subjected to Western blotting with anti-BRAF mAb (CST), RAF1 mAb, or actin as a control. The results show progressive decline in RAF1 activation domain phospho-Ser338 in YUDOSO-BRAF WT cells treated with PLX4032 probably dues to reduced levels of the protein in this fraction of the cell lysates. Likewise, the decline in phospho-Ser259, the inhibitory site, after 1 h treatmentmwith PLX4032 also correlated with reduced levels of total RAF1 protein (compare phospho-pRAF1 (S259)to RAF1). In contrast, there was a significant increase in phospho-RAF1 (Ser289/296/301), the MAPK phosphorylation sites that persisted in BRAF wild-type cells treated with the drug, shown in B. Figure S4 : Suppression of MEKK3 activity in response to PLX4032. YUDOSO-BRAF WT melanoma cells were treated with PLX4032 (1 µM) for 1 h, harvested and MEKK3 immune-complexes were subjected to RAF1 kinase cascade assay in the absence of MEK as an intermediary. Kinase activity is expressed as picomoles [γ-32 P]-ATP incorporated into MBP. Each data point is an average of triplicate measurements ± STDV. The panels under each kinase assay shows Western blots of immunoprecipitated proteins eluted with SDS sample buffer and probed with antibodies to the MEKK3. There was no significant MEKK3 activity in YULAC-BRAF V600E cells (data not shown), although equal amounts of protein were present in the immunoprecpitated material (data not shown). 
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